PCRX — PharmaCorp Rx Cashflow Statement
0.000.00%
Last trade - 00:00- CA$55.72m
- CA$44.00m
- CA$5.79m
- 50
- 19
- 41
- 29
Annual cashflow statement for PharmaCorp Rx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.026 | -0.517 | -0.47 | -1.05 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | 0 | 0.386 | 0 | 0.316 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.026 | 0.011 | -0.049 | 0.708 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Taxes Payable | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | 0.001 | -0.12 | -0.519 | 0.125 |
| Capital Expenditures | — | — | — | -0.007 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | — | -16.9 |
| Acquisition of Business | ||||
| Cash from Investing Activities | — | — | — | -16.9 |
| Financing Cash Flow Items | -0.021 | -0.126 | 0 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.98 | 1.87 | 0.028 | 27.4 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.98 | 1.75 | -0.492 | 10.6 |